Close Menu

NEW YORK – Rare disease diagnostics and research firm Centogene said on Thursday that it plans to sell a total of 3.5 million common shares in a primary and secondary public stock offering.

The offering consists of 2 million common shares offered by the company and 1.5 million common shares offered by selling shareholders at a price of $14 per share, for gross proceeds of $28 million and $21 million, respectively. Centogene will not receive any proceeds from the sale by the selling shareholders.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.